A citation-based method for searching scientific literature

Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
Times Cited: 363



Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Steven P Marso, Peter Öhman, Neha J Pagidipati, Neil Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez. N Engl J Med 2017
Times Cited: 802




List of shared articles



Times cited

Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction.
Marco Trevisan, Edouard L Fu, Karolina Szummer, Anna Norhammar, Pia Lundman, Christoph Wanner, Arvid Sjölander, Tomas Jernberg, Juan Jesus Carrero. Eur Heart J Cardiovasc Pharmacother 2021
2

Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Yoshitaka Shirakura, Kentaro Azuma, Ryoko Fujiwara, Hiroka Takahashi, Kazuya Murata. Heart Fail Rev 2021
2


Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.
Taufiq Salahuddin, Vanessa Richardson, Demetria M McNeal, Kamal Henderson, Paul L Hess, Sridharan Raghavan, David R Saxon, Javier A Valle, Stephen W Waldo, P Michael Ho,[...]. Diabetes Obes Metab 2021
0


Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist.
Hertzel C Gerstein, Kelley Branch, Laura Heenan, Stefano Del Prato, Nardev S Khurmi, Carolyn S P Lam, Richard Pratley, Julio Rosenstock, Naveed Sattar. Diabetes Obes Metab 2021
4

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Michael A Nauck, Daniel R Quast, Jakob Wefers, Juris J Meier. Mol Metab 2021
34



Effects of exenatide on microvascular reactivity in patients with type 2 diabetes and coronary artery disease: A randomized controlled study.
Nikolaos Östlund Papadogeorgos, Jeanette Kuhl, Angela Shore, Thomas Kahan, Gun Jörneskog, Majid Kalani. Microcirculation 2021
0

Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.
Nikolaus Marx, Melanie J Davies, Peter J Grant, Chantal Mathieu, John R Petrie, Francesco Cosentino, John B Buse. Lancet Diabetes Endocrinol 2021
19

Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.
Ronald M Goldenberg, Vineeta Ahooja, Kristin K Clemens, Jeremy D Gilbert, Megha Poddar, Subodh Verma. Can J Diabetes 2021
1

Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.
Radica Z Alicic, Emily J Cox, Joshua J Neumiller, Katherine R Tuttle. Nat Rev Nephrol 2021
14

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Takayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, Nitin Chopra, Hirotaka Miyashita, Takahisa Mikami, Hiroki Ueyama, Tomohiro Fujisaki, Yusuke Saigusa, Takahiro Yamaji,[...]. Cardiovasc Diabetol 2021
7

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials.
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, Alessandro Csermely, Amedeo Lonardo, Giovanni Targher. Metabolites 2021
14

Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial.
Aung Myat, Simon R Redwood, Satpal Arri, Bernard J Gersh, Deepak L Bhatt, Michael S Marber. Diabetol Metab Syndr 2021
1

Is cardioprotection with GLP-1 receptor agonists a class effect?
Lars Rydén, Giulia Ferrannini, Linda Mellbin. Eur J Prev Cardiol 2021
0

Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes.
Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini. Eur J Prev Cardiol 2021
3

Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome.
Muhammad Imtiaz Ahmad, Michael D Shapiro. Curr Atheroscler Rep 2021
1

GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.
Thomas Karagiannis, Apostolos Tsapas, Eleni Athanasiadou, Ioannis Avgerinos, Aris Liakos, David R Matthews, Eleni Bekiari. Diabetes Res Clin Pract 2021
4


Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis.
Marianne Benn, Frida Emanuelsson, Anne Tybjærg-Hansen, Børge G Nordestgaard. Diabetologia 2021
1

Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.
Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J L Heersprink, Mikhail Kosiborod, Christoph Wanner, Eberhard Standl. Cardiovasc Diabetol 2021
1



Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation.
Lale A Ertuglu, Esteban Porrini, Mads Hornum, Atalay Demiray, Baris Afsar, Alberto Ortiz, Adrian Covic, Peter Rossing, Mehmet Kanbay. Transpl Int 2021
1

Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art Review.
Henri Honka, Carolina Solis-Herrera, Curtis Triplitt, Luke Norton, Javed Butler, Ralph A DeFronzo. J Am Coll Cardiol 2021
0

The impact of diabetes on heart failure development: The cardio-renal-metabolic connection.
Paul Valensi, Gaétan Prévost, Sara Pinto, Jean-Michel Halimi, Erwan Donal. Diabetes Res Clin Pract 2021
0



Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.
Carlos E Barbery, Anna Giczewska, Jennifer White, Yuliya Lokhnygina, Robert John Mentz, Rury R Holman, Neha Pagidipati, Adrian F Hernandez, W Schuyler Jones. Am Heart J 2021
0

Heart failure outcomes and glucagon-like peptide-1 receptor agonists: A systematic review of observational studies.
Omar S Alkhezi, Haifa A Alsuhaibani, Amal A Alhadyab, Mashael E Alfaifi, Basmah Alomrani, Ali Aldossary, Osamah M Alfayez. Prim Care Diabetes 2021
0


Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Jack Wei Chieh Tan, David Sim, Junya Ako, Wael Almahmeed, Mark E Cooper, Jamshed J Dalal, Chaicharn Deerochanawong, David Wei Chun Huang, Sofian Johar, Upendra Kaul,[...]. Eur Cardiol 2021
0

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients.
Kazushi Uneda, Yuki Kawai, Takayuki Yamada, Sho Kinguchi, Kengo Azushima, Tomohiko Kanaoka, Yoshiyuki Toya, Hiromichi Wakui, Kouichi Tamura. Sci Rep 2021
1